AFP and hepatocellular carcinoma: On the other hand, in a multicenter cohort study of 1675 patients who achieved SVR following treatment with DAA therapy, Ogawa et al. showed that the 1-year cumulative de-novo HCC rates were 1.4 and 13.1% in the end-of-treatment AFP < 9.0 ng/mL group and AFP ≥ 9.0 ng/mL group, respectively (log-rank test p < 0.001) [50].